Cargando…

Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer

Objectives: To develop and validate a predictive model for discriminating clinically significant prostate cancer (csPCa) from clinically insignificant prostate cancer (ciPCa). Methods: This retrospective study was performed with 159 consecutively enrolled pathologically confirmed PCa patients from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yongsheng, Chen, Wen, Yue, Xianjie, Shen, Jianliang, Gao, Chen, Pang, Peipei, Cui, Feng, Xu, Maosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339043/
https://www.ncbi.nlm.nih.gov/pubmed/32695660
http://dx.doi.org/10.3389/fonc.2020.00888
_version_ 1783554810343063552
author Zhang, Yongsheng
Chen, Wen
Yue, Xianjie
Shen, Jianliang
Gao, Chen
Pang, Peipei
Cui, Feng
Xu, Maosheng
author_facet Zhang, Yongsheng
Chen, Wen
Yue, Xianjie
Shen, Jianliang
Gao, Chen
Pang, Peipei
Cui, Feng
Xu, Maosheng
author_sort Zhang, Yongsheng
collection PubMed
description Objectives: To develop and validate a predictive model for discriminating clinically significant prostate cancer (csPCa) from clinically insignificant prostate cancer (ciPCa). Methods: This retrospective study was performed with 159 consecutively enrolled pathologically confirmed PCa patients from two medical centers. The dataset was allocated to a training group (n = 54) and an internal validation group (n = 22) from one center along with an external independent validation group (n = 83) from another center. A total of 1,188 radiomic features were extracted from T2WI, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) images derived from DWI for each patient. Multivariable logistic regression analysis was performed to develop the model, incorporating the radiomic signature, ADC value, and independent clinical risk factors. This was presented using a radiomic nomogram. The receiver operating characteristic (ROC) curve was utilized to assess the predictive efficacy of the radiomic nomogram in both the training and validation groups. The decision curve analysis was used to evaluate which model achieved the most net benefit. Results: The radiomic signature, which was made up of 10 selected features, was significantly associated with csPCa (P < 0.001 for both training and internal validation groups). The area under the curve (AUC) values of discriminating csPCa for the radiomics signature were 0.95 (training group), 0.86 (internal validation group), and 0.81 (external validation group). Multivariate logistic analysis identified the radiomic signature and ADC value as independent parameters of predicting csPCa. Then, the combination nomogram incorporating the radiomic signature and ADC value demonstrated a favorable classification capability with the AUC of 0.95 (training group), 0.93 (internal validation group), and 0.84 (external validation group). Appreciable clinical utility of this model was illustrated using the decision curve analysis for the nomogram. Conclusions: The nomogram, incorporating radiomic signature and ADC value, provided an individualized, potential approach for discriminating csPCa from ciPCa.
format Online
Article
Text
id pubmed-7339043
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73390432020-07-20 Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer Zhang, Yongsheng Chen, Wen Yue, Xianjie Shen, Jianliang Gao, Chen Pang, Peipei Cui, Feng Xu, Maosheng Front Oncol Oncology Objectives: To develop and validate a predictive model for discriminating clinically significant prostate cancer (csPCa) from clinically insignificant prostate cancer (ciPCa). Methods: This retrospective study was performed with 159 consecutively enrolled pathologically confirmed PCa patients from two medical centers. The dataset was allocated to a training group (n = 54) and an internal validation group (n = 22) from one center along with an external independent validation group (n = 83) from another center. A total of 1,188 radiomic features were extracted from T2WI, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) images derived from DWI for each patient. Multivariable logistic regression analysis was performed to develop the model, incorporating the radiomic signature, ADC value, and independent clinical risk factors. This was presented using a radiomic nomogram. The receiver operating characteristic (ROC) curve was utilized to assess the predictive efficacy of the radiomic nomogram in both the training and validation groups. The decision curve analysis was used to evaluate which model achieved the most net benefit. Results: The radiomic signature, which was made up of 10 selected features, was significantly associated with csPCa (P < 0.001 for both training and internal validation groups). The area under the curve (AUC) values of discriminating csPCa for the radiomics signature were 0.95 (training group), 0.86 (internal validation group), and 0.81 (external validation group). Multivariate logistic analysis identified the radiomic signature and ADC value as independent parameters of predicting csPCa. Then, the combination nomogram incorporating the radiomic signature and ADC value demonstrated a favorable classification capability with the AUC of 0.95 (training group), 0.93 (internal validation group), and 0.84 (external validation group). Appreciable clinical utility of this model was illustrated using the decision curve analysis for the nomogram. Conclusions: The nomogram, incorporating radiomic signature and ADC value, provided an individualized, potential approach for discriminating csPCa from ciPCa. Frontiers Media S.A. 2020-06-30 /pmc/articles/PMC7339043/ /pubmed/32695660 http://dx.doi.org/10.3389/fonc.2020.00888 Text en Copyright © 2020 Zhang, Chen, Yue, Shen, Gao, Pang, Cui and Xu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Yongsheng
Chen, Wen
Yue, Xianjie
Shen, Jianliang
Gao, Chen
Pang, Peipei
Cui, Feng
Xu, Maosheng
Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer
title Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer
title_full Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer
title_fullStr Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer
title_full_unstemmed Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer
title_short Development of a Novel, Multi-Parametric, MRI-Based Radiomic Nomogram for Differentiating Between Clinically Significant and Insignificant Prostate Cancer
title_sort development of a novel, multi-parametric, mri-based radiomic nomogram for differentiating between clinically significant and insignificant prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339043/
https://www.ncbi.nlm.nih.gov/pubmed/32695660
http://dx.doi.org/10.3389/fonc.2020.00888
work_keys_str_mv AT zhangyongsheng developmentofanovelmultiparametricmribasedradiomicnomogramfordifferentiatingbetweenclinicallysignificantandinsignificantprostatecancer
AT chenwen developmentofanovelmultiparametricmribasedradiomicnomogramfordifferentiatingbetweenclinicallysignificantandinsignificantprostatecancer
AT yuexianjie developmentofanovelmultiparametricmribasedradiomicnomogramfordifferentiatingbetweenclinicallysignificantandinsignificantprostatecancer
AT shenjianliang developmentofanovelmultiparametricmribasedradiomicnomogramfordifferentiatingbetweenclinicallysignificantandinsignificantprostatecancer
AT gaochen developmentofanovelmultiparametricmribasedradiomicnomogramfordifferentiatingbetweenclinicallysignificantandinsignificantprostatecancer
AT pangpeipei developmentofanovelmultiparametricmribasedradiomicnomogramfordifferentiatingbetweenclinicallysignificantandinsignificantprostatecancer
AT cuifeng developmentofanovelmultiparametricmribasedradiomicnomogramfordifferentiatingbetweenclinicallysignificantandinsignificantprostatecancer
AT xumaosheng developmentofanovelmultiparametricmribasedradiomicnomogramfordifferentiatingbetweenclinicallysignificantandinsignificantprostatecancer